

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 30, 2023**

---

**ACASTI PHARMA INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Quebec**  
(State or Other Jurisdiction  
of Incorporation)

**001-35776**  
(Commission File Number)

**98-1359336**  
(IRS Employer  
Identification No.)

**3009, boul. de la Concorde East  
Suite 102  
Laval, Quebec**  
(Address of Principal Executive Offices)

**H7E 2B5**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 450 686-4555**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value per share	ACST	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 30, 2023, Mr. Jean-Marie (John) Canan resigned from the board of directors of Acasti Pharma Inc. (the "Company"), effective immediately. Mr. Canan was also a member of the Company's audit committee and governance and human resources committee. Mr. Canan's resignation was not the result of any dispute or disagreement with the Company or the Company's board of directors on any matter relating to the operations, policies or practices of the Company.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Acasti Pharma Inc.**

Date: March 31, 2023

By: /s/ Jan D'Alvise  
Jan D'Alvise, Chief Executive Officer

---

